Abstract
Over the past decade, adenovirus (Ad)-based vectors have been used extensively in the context of cancer gene therapy. Two basic strategies have been pursued for the use of Ad vectors in cancer gene therapy: 1) approaches aimed at direct tumor cell killing through delivery of replicating oncolytic viruses or non-replicating vectors encoding tumor suppressor genes, suicide genes or anti-angiogenic genes, and 2) immunotherapeutic approaches aimed at inducing host antitumor immune responses that can destroy tumor cells at both primary and metastatic locations. Both strategies offer the potential of selective tumor cell destruction without damage to normal tissues. Extensive pre-clinical and clinical studies have been conducted based on these strategies. Encouraging results have been obtained but robust clinical efficacy remains elusive. Several obstacles limiting the therapeutic activity of Ad vectors have been encountered, including efficiency of tumor cell transduction and inhibition of efficacy by anti-Ad host immune responses. However, expanding knowledge in the areas of Ad biology and tumor biology continues to lead to increasingly sophisticated approaches to address these issues. A review of various Ad-based cancer gene therapy approaches and recent progress in the area are presented herein.
Keywords: Immunotherapy, tumor, vaccine, dendritic cells, suicide gene, vector, xenograft, oncolysis
Current Gene Therapy
Title: Adenovirus-Based Cancer Gene Therapy
Volume: 5 Issue: 6
Author(s): Johanne M. Kaplan
Affiliation:
Keywords: Immunotherapy, tumor, vaccine, dendritic cells, suicide gene, vector, xenograft, oncolysis
Abstract: Over the past decade, adenovirus (Ad)-based vectors have been used extensively in the context of cancer gene therapy. Two basic strategies have been pursued for the use of Ad vectors in cancer gene therapy: 1) approaches aimed at direct tumor cell killing through delivery of replicating oncolytic viruses or non-replicating vectors encoding tumor suppressor genes, suicide genes or anti-angiogenic genes, and 2) immunotherapeutic approaches aimed at inducing host antitumor immune responses that can destroy tumor cells at both primary and metastatic locations. Both strategies offer the potential of selective tumor cell destruction without damage to normal tissues. Extensive pre-clinical and clinical studies have been conducted based on these strategies. Encouraging results have been obtained but robust clinical efficacy remains elusive. Several obstacles limiting the therapeutic activity of Ad vectors have been encountered, including efficiency of tumor cell transduction and inhibition of efficacy by anti-Ad host immune responses. However, expanding knowledge in the areas of Ad biology and tumor biology continues to lead to increasingly sophisticated approaches to address these issues. A review of various Ad-based cancer gene therapy approaches and recent progress in the area are presented herein.
Export Options
About this article
Cite this article as:
Kaplan M. Johanne, Adenovirus-Based Cancer Gene Therapy, Current Gene Therapy 2005; 5 (6) . https://dx.doi.org/10.2174/156652305774964677
DOI https://dx.doi.org/10.2174/156652305774964677 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Enhanced Floating and Intragastric Release of 5-Flourouracil through Sesame Oil Entrapped Gellan Composite Hydrogel Beads
Current Drug Therapy Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Pathophysiology of Erectile Dysfunction
Current Drug Targets Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Phosphorothioate-Stimulated Uptake of siRNA by Mammalian Cells: A Novel Route for Delivery
Current Topics in Medicinal Chemistry DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry